AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

GRANULIN-EPITHELIN PRECURSOR (GEP) OVEREXPRESSION AS A TARGET FOR DIAGNOSIS, PROGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)

Summary

This invention further provides methods for determining whether an agent causes a reduction in the activity of a Granulin-Epithelin Precursor (CEP) protein in a cell. This invention also provides methods for reducing the expression of Granulin-Epithelin Precursor (CEP) protein in a cell. This invention also provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC). This invention provides methods for determining whether a subject is afflicted with Hepatocellular carcinoma (HCC). This invention further provides a method for treating a subject afflicted with Hepatocellular carcinoma (HCC) comprising administering to the subject a therapeutically effective amount of an agent which specifically interferes with the expression of the Granulin-Epithelin Precursor (CEP) protein in the tumor cells of the subject.

Supplementary Information

Patent Number: US20050244839A1
Application Number: US2004836390A
Inventor: Cheung, Siu | Fan, Sheung
Priority Date: 29 Apr 2004
Priority Number: US20050244839A1
Application Date: 29 Apr 2004
Publication Date: 3 Nov 2005
IPC Current: A61P003500 | C07K001400 | C12Q000168 | G01N0033574
US Class: 435005 | 435006 | 43500613 | 43500723
Title: Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC)
Usefulness: Granulin-epithelin precursor (GEP) overexpression as a target for diagnosis, prognosis and treatment of hepatocellular carcinoma (HCC)
Summary: The method is useful for determining whether an agent causes a reduction in the expression or activity of GEP protein in a cell. The agent, which interferes with the expression of the GEP protein in the cell, is useful for reducing the expression of GEP protein in a cell, for diagnosing hepatocellular carcinoma (HCC), and treating a subject afflicted with HCC. (All claimed).
Novelty: Determining whether an agent causes reduction in expression/activity of Granulin-Epithelin Precursor (GEP) protein, by comparing amount of GEP protein expression/activity in the presence or absence of the agent

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Application No.

US2004836390A

Country/Region

Hong Kong

For more information, please click Here